Arcutis Biotherapeutics, Inc. (ARQT) Tops Q3 EPS by 9c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q3 EPS of ($0.33), $0.09 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $44.75 million versus the consensus estimate of $37.62 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Circle board member resigns after nearly 13 years of service
• Battery X Metals adds auto industry advisor to board